No impact on Covaxin safety, clarifies Bharat Biotech after WHO suspension

"It does not indicate a change in risk-benefit ratio (for Covaxin) and the data, available to WHO, indicates the vaccine is effective and no safety concern exists," it said.;

Published On 2022-04-04 07:36 GMT | Update On 2022-04-04 07:39 GMT

New Delhi: Hyderabad-based Bharat Biotech on Sunday issued a clarification that there is "no impact on efficacy and safety of the COVID-19 vaccine COVAXIN" after the World Health Organisation suspended it from its Covax facility.

"For the millions who have received COVAXIN, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine," read the statement issued by Bharat Biotech on suspension from WHO.

The vaccine manufacturer has further said that the company is slowing down the production of Covaxin for facility optimization.

"For the coming period the company will focus on pending facility maintenance, process and facility optimization activities," the statement read.

"As all existing facilities were repurposed for the manufacture of COVAXIN, with continuous production during the past year, to meet the public health emergency of COVID-19, these upgrades were due. Certain highly sophisticated equipment which was required to enhance the process stringency was unavailable during the COVID-19 pandemic. It has to be stressed that the quality of COVAXIN was never compromised at any point in time," it added.

The company also mentioned that they are working to further improvements and upgrades to ensure that the production of COVAXIN continues to meet the increasing global regulatory requirements.

"Notwithstanding this excellent safety and efficacy record, Bharat Biotech is diligently working to further improvements and upgrades to ensure that the production of COVAXIN continues to meet ever-increasing global regulatory requirements. Since patient safety is the primary consideration for any new vaccine, there can be no compromises in meeting operational excellence objectives," it said.

The Bharat Biotech's COVID-19 vaccine, COVAXIN has been suspended by World Health Organization (WHO) from its Covax facility, announced the UN health body on Saturday attributing it to deficiencies in manufacturing practices.

"WHO confirms the suspension of supply of COVAXIN produced by Bharat (Biotech), through UN procurement agencies and recommending to countries that received the vaccine to take actions as appropriate," reads the WHO in a statement.

However, the UN body clarified that there will be no issues related to the safety and efficacy of a vaccine.

"The risk assessment to date does not indicate a change in the risk-benefit ratio. The data available to WHO, indicate the vaccine is effective and no safety concern exists. For continuation of vaccination with alternative sources of COVID19 vaccines countries should refer to the respective SAGE recommendation," it read.

On inspection by WHO, Bharat biotech said, "During the recent WHO post-EUL inspection, Bharat Biotech agreed with the WHO team on the scope of the planned improvement activities and indicated that they will be executed as soon as practical."

"It does not indicate a change in the risk-benefit ratio (for Covaxin) and the data, available to WHO, indicates the vaccine is effective and no safety concern exists," it said.

This suspension has been done after the WHO post-emergency use listing inspection that was conducted between March 14-22. After the suspension, there will be an interruption of supply of Covaxin production for export.

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

No impact on Covaxin safety, clarifies Bharat Biotech after WHO suspension

"It does not indicate a change in risk-benefit ratio (for Covaxin) and the data, available to WHO, indicates the vaccine is effective and no safety concern exists," it said.;

Similar News

Indian pharma market registers 7.9 percent growth in July: Report

Aragen appoints Aniel Khubchandani as CEO of Development and Manufacturing Solutions business

Mounjaro, Wegovy sales in India double on month in July

Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update

CDSCO Panel Approves New Indications for Novo Nordisk's Semaglutide, Mandates PMS Study

Intas Pharma Gets Expert Panel Nod For PMS Data On Tofacitinib Ointment In Atopic Dermatitis

Axplora invests Euro 6.5 million to expand production capacity at Vizag site

NPPA Slapped Rs 9,950 Cr Penalty On Pharma Firms, Recovered Only 14.25%